Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
Prices via Intrinio. Supplier and customer ties are extracted from SEC filings and carry the sentence they came from. Not investment advice.
High 2.10 at 11:00 am ET, low 2.09 at 10:15 am ET.
the bull case· 1
4
disclosed supplier and customer ties in SEC filings
sec filingsedgarthe bear case· 4
83
managers reporting a position in the latest quarterly filings
13fJun 30 '2613
managers whose positions together make up four fifths of the reported value
13fJun 30 '2610 of 16
of the largest reporting managers cut their stake in the latest quarter
13fJun 30 '26−15.74%
change in shares held by the ten largest reporting managers over the latest quarter
13fJun 30 '26Sides and captions by the model; every figure is ours. Built Sep 16 '26 for the Apr 29 '27 report. Not a forecast, not advice.
Of the 5 companies TuHURA Biosciences, Inc. moves with most closely, none share its SEC classification.
Measured against 202 trading days of our own closes. Co-movement, not cause.
SIC 2834, Pharmaceutical Preparations, from each company's own filings. Largest first.
82 managers report a position worth $20.9M between them, and 13 of them hold 80% of it.
tall tick = annual report · 1 on record
TuHURA Biosciences, Inc.
Price, suppliers and customers from SEC filings, institutional ownership and the next report.
Nasdaq · Pharmaceutical Preparations
TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA’s lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.
HURA (TuHURA Biosciences, Inc.) has 4 disclosed suppliers and 0 disclosed customers, strongest disclosure first.
Suppliers:
Select a tie for its filing sentence; select again to open the company. Nearer the centre, the more the filings disclose. Extended: satellites hang off single companies, not bundled sectors.